Skip to main content
OpenTrials
Completed

NCT Number: NCT01700439

Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve

The purpose of the clinical study is to prove that the heart valve device is safe, effective, and performs as intended.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Keck Hospital of University of Southern California, Los Angeles, California, United States

Loading trial locations.

About this study

This is a prospective, non-randomized, multi-center trial. Up to 950 subjects will be enrolled at up to 35 centers in the US. After replacement of their aortic heart valve with the EDWARDS INTUITY valve system, each patient will have routine follow-up tests at the following intervals: discharge, 3 months, 1 year, and annually thereafter for a minimum of five years.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Inclusion Criteria - Subjects will be required to meet all inclusion criteria:
  • Male or female, age 18 years or older
  • Has aortic stenosis or stenosis-insufficiency of an aortic valve requiring a planned replacement as indicated in the preoperative evaluation
  • Is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery
  • Provide written informed consent
  • Geographically stable and agrees to attend follow-up assessments until all subjects have completed 5 years of follow up

Exclusion criteria

  • Exclusion Criteria - Subjects will not be eligible for trial participation if any of the following criteria are present:
  • Pure aortic insufficiency
  • Requires emergency surgery
  • Previous aortic valve replacement
  • Had prior mitral, tricuspid or pulmonic valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ
  • Requires multiple valve replacement/repair
  • Requires a surgical procedure outside of the cardiac area (e.g., vascular endarterectomy, vascular bypass, tumor removal)
  • Aneurysm of the aortic root and/or ascending aorta requiring surgical intervention
  • Active endocarditis/myocarditis or endocarditis/ myocarditis within 3 months prior to the scheduled AVR surgery
  • Myocardial infarction (MI) within thirty (30) days prior to valve replacement surgery
  • Renal insufficiency as determined by creatinine ≥ 2.5 mg/dL at screening or end-stage renal disease requiring chronic dialysis
  • Hyperparathyroidism
  • MRI or CT-scan confirmed cerebrovascular accident (CVA), or transient ischemic attack (TIA) within 6 months (180 days) of the procedure
  • Presence of non-cardiac disease limiting life expectancy to less than 12 months
  • Hypertrophic obstructive cardiomyopathy (HOCM)
  • Left ventricular ejection fraction ≤ 25%
  • Documented history of substance (drug or alcohol) abuse within the last 5 years
  • Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation
  • Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to the procedure
  • Pregnancy, lactation, or planning to become pregnant;
  • Currently incarcerated or unable to give voluntary informed consent
  • Leucopenia (WBC < 3.5x 103/µL), or acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L), or thrombocytopenia (platelet count < 50x 103/µL), or history of bleeding diathesis or coagulopathy
  • History of myxomatous disease/connective tissue disorders (e.g., Marfan's Syndrome)
  • Current or recent participation (within 6 weeks prior to surgery) in an investigational drug or device trial
  • Intra-operative Exclusion Criteria
  • Anatomic variances which contraindicate implant of the trial valve, such as:
  • anomalous coronary arteries
  • annular deformation or extensive calcification of the annulus or aortic root which cannot be removed
  • significant calcium on the anterior mitral leaflet
  • pronounced septal calcification
  • position of coronary ostia relative to Model 8300ACD valve that would result in obstruction of blood flow
  • Available devices are not suitably sized for the subject's annulus

Treatment and study plan

EDWARDS INTUITY valve

Device

Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.

Primary outcomes

  1. Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort

    Time frame: Events occurring ≥ 31 days and up through 8 years post-implant

    Late patient years are calculated from 31 days post-implant to the date of the last follow-up visits (or contact) or adverse events. Late Patient year calculation:[(Number of late adverse events/sum of late patient years) x 100]

Secondary outcomes

  1. Percentage of Subjects With Edwards INTUITY Surgical Aortic Heart Valve Device Technical Success

    Time frame: Day of procedure

    Device technical success is defined as the successful delivery and deployment of the aortic trial heart valve with maximum of two attempts and subject leaving the operating room (OR) with valve in place.

  2. Percentage of Subjects With Edwards INTUITY Surgical Heart Valve Procedural Success

    Time frame: Day of procedure through discharge or 10 days post index procedure, whichever comes first.

    Procedural success is defined as device technical success followed by the absence of adverse events resulting in device reoperation implant of permanent pacemaker (with baseline sinus rhythm and no other pre-existing conduction issues), or valve-related death within discharge or 10 days post index procedure, whichever comes first.

  3. Average Amount of Time Subject Spent on Cardiopulmonary Bypass

    Time frame: Day of procedure

    Surgical and hospitalization factors - Cardiopulmonary bypass time

  4. Average Subject Time on Cardiopulmonary Cross Clamp

    Time frame: Day of procedure

    Surgical and hospitalization factors - Cardiopulmonary cross clamp time

  5. Average Number of Days Subjects Were in the Intensive Care Unit (ICU)

    Time frame: Day of procedure through discharge from the hospital

    Length of time surgical subjects were in the intensive care unit (ICU) after their heart valve replacement procedure.

  6. Subject's New York Heart Association (NYHA) Classification Over Time

    Time frame: Baseline, 3-months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8 Years

    The New York Heart Association (NYHA) functional classification system relates symptoms to everyday activities and the patient's quality of life. Class I. Patients with cardiac disease but without resulting limitation of physical activity.

    Class II. Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest.

    Class III. Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest.

    Class IV. Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort.

    Symptoms of heart failure or the anginal syndrome may be present even at rest.

  7. Subject's Average Mean Gradient Measurements Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8-Years follow-up

    Mean gradient is the average flow of blood through the aortic valve measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher value is considered worse, and a lower value is considered better but the value is dependent on the size and type of valve.

  8. Subject's Average Peak Gradient Measurements Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8-Years follow-up

    Peak gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury. Gradients are evaluated by echocardiography over time. In general, a higher valve is considered worse, and a lower value is considered better, but the value is dependent on the size and type of valve.

  9. Subject's Effective Orifice Area (EOA) Measurement Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Effective orifice area represents the cross-sectional area of the blood flow downstream of the aortic valve. Effective orifice area is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size and type of valve.

  10. Subject's Effective Orifice Area Index (EOAI) Measurement Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Effective orifice area index represents the minimal cross-sectional area of the blood flow downstream of the mitral valve divided by the person's body surface area. Effective orifice area index is evaluated by echocardiography over time. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient and the size and type of valve.

  11. Subject's Performance Index Measurement Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Performance index is defined as the subject's effective orifice area (the cross-sectional area of the blood flow downstream of the aortic valve) divided by the subject's native orifice area. Performance Index is evaluated by echocardiography over time and are dependent on the size and type of the valve. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient and the size and type of valve.

  12. Subject's Cardiac Output Measurement at Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Cardiac output is the amount of blood the heart pumps through the circulatory system in a minute. Cardiac output is evaluated by echocardiography over time. Normal cardiac output in healthy volunteers over 60 years of age was reported between 3.1 and 6.4 liters per minute. In general, a higher value is considered better, and a lower value is considered worse.

  13. Subject's Cardiac Index Measurement Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Hemodynamic performance - Cardiac index (CI) evaluated by echocardiography. Cardiac index is an assessment of the cardiac output value based on the patient's size. To obtain the cardiac index, divide the cardiac output by the person's body surface area (BSA). Cardiac Index is a useful marker of how well the heart is functioning as a pump by directly correlating the volume of blood pumped by the heart with an individual's body surface area. Normal cardiac output index in healthy volunteers over 60 years of age was reported between 1.1 and 3.2 L/min/m^2. In general, a higher value is considered better, and a lower value is considered worse, but the value is dependent on the size of the patient.

  14. Amount of Aortic Valvular Regurgitation in Subjects Over Time by Valve Size

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation. Higher numbers on the scale show a worsening outcome.

Other outcomes

  1. Subject's Average Score at Baseline and 1 Year on the Quality of Life Survey

    Time frame: Baseline and one year follow-up

    The Medical Outcomes Study Short-Form 12 (SF-12) - physical and metal states. The SF-12 questionnaire scale ranges from 100, which reflects the best health status to 0, which reflects the worst health status.

  2. Subject's Average White Blood Cell Count Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Laboratory analysis of White Blood Cell (WBC) count on blood drawn from subject; WBC fight infection. The normal reference range for WBC count is 4.5 to 10 10^3 cells/microliters. In general, results either lower or higher than the normal range can indicate something is wrong.

  3. Subject's Average Red Blood Cell Count Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    The red blood cell (RBC) count is a test that measures the number of oxygen-carrying blood cells in your blood. The red blood cell count normal range for women is 4.2 to 5.4 10^6 cells/microliters and for men is 4.7 to 6.1 10^6 cells/microliters. A high red blood cell count may indicate that you have a condition that's preventing you from getting enough oxygen. A low RBC may be caused by an infection, or a medical condition related to anemia. In general, results either lower or higher than the normal range can indicate something is wrong.

  4. Subject's Average Hematocrit Percentage Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Laboratory Analysis of Hematocrit Percentage on blood drawn from subjects. A hematocrit test measures the proportion of red blood cells in your blood. Red blood cells carry oxygen throughout your body. Having too few or too many red blood cells can be a sign of certain diseases. Normal hematocrit ranges for adult females are 36% to 44% and for adult males are 41% to 50%. In general, results either lower or higher than the normal range can indicate something is wrong.

  5. Subject's Average Hemoglobin Percentage Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Laboratory Analysis of Hemoglobin Count on blood drawn from subjects. Hemoglobin is an oxygen-carrying protein in red blood cells. In males, a healthy hemoglobin level is between 13.2 and 16.6 g/dL. In females, a hemoglobin count of between 11.6 and 15 g/dL is considered normal and healthy. In general, results either lower or higher than the normal range can indicate something is wrong.

  6. Subject's Average Plasma Free Hemoglobin Over Time

    Time frame: Discharge, 3 months, 1-, 2-, 3-, 4-, 5-, 6-, 7-, and 8- Years follow-up

    Laboratory Analysis of Plasma Free Hemoglobin (Hgb) of blood drawn from subject. This blood test measures the level of free hemoglobin in the plasma (liquid portion of the blood). The reference range for plasma free hemoglobin is 0.0 to 15.2 mg/dL. In general, values higher than this can indicate something is wrong.

Sponsors and collaborators

Lead sponsor

Edwards Lifesciences

Industry

Registry information

Official study title

Multi-CenTer Experience With the Rapid Deployment EDWARDS INTUITY Valve System FOR Aortic Valve ReplaceMent

Acronym: TRANSFORM™

Important dates

Study start
2012
Primary completion
2021
Study completion
2021
First posted
Oct 4, 2012
Registry last updated
May 19, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.